Early detection of ovarian cancer has the potential to save millions of lives and preserve reproductive choices. While previous proteomics-based efforts have led to commercial blood tests for ovarian cancer, their performance has not been sufficient for widespread clinical impact. One challenge has been the need for improved biomarker specificity and sensitivity—an area where glycoproteomics offers a promising solution.
In this plenary talk, I will introduce LeMBA-MS, our next-generation glycoproteomics platform designed to overcome key technological barriers in biomarker discovery and translation. By integrating lectin magnetic bead arrays with mass spectrometry, LeMBA-MS enables single step glycoform enrichment with high reproducibility that is critical for clinical translation. Combined with our clinical assay development strategy, this platform supports the creation of a fit-for-purpose diagnostic test for ovarian cancer.
Beyond the technology, I will highlight the importance of multidisciplinary collaboration in bridging the gap between scientific innovation and real-world application. By combining expertise in glycoproteomics, clinical science, data analytics, and diagnostic development, we are working to translate promising biomarker discoveries into a robust, clinically impactful product. I will also share my personal journey from scientist to biotech entrepreneur, navigating the challenges of commercialization and strategic partnerships in the deep-tech space.